Pfizer Inc.’s first phase III study of Tofacitinib in psoriatic arthritis, dubbed OPAL Broaden, has met its primary efficacy endpoints. Another phase III study, dubbed OPAL Beyond, is underway, and results are anticipated in the first half of 2016.
Forex – financial instrument.Forex news
Pfizer Inc.’s first phase III study of Tofacitinib in psoriatic arthritis, dubbed OPAL Broaden, has met its primary efficacy endpoints. Another phase III study, dubbed OPAL Beyond, is underway, and results are anticipated in the first half of 2016.